Boston Children's Hospital
Boston, Massachusetts, 02115, United States
NCT Number: NCT03073122
In the landmark Boston Circulatory Arrest Study, neurologic and developmental status was measured following infant heart surgery and then prospectively at ages 1, 2.5, 4, 8, and 16 years, with findings of significant neurocognitive deficits and brain MRI abnormalities regardless of operative management. To date, no study has evaluated the neuropsychological and neuroimaging antecedents and correlates of well-being in adults with congenital heart disease, a population now >1 million and projected to grow at 5% per year. The investigators propose to study the Boston cohort at ages 24-29 years to assess the associations of adult well-being with childhood and adolescent executive function, other measures of mental health and cognitive function, adolescent brain MRI findings, and clinical variables; findings will guide the design of interventions in childhood to optimize outcomes in adults with congenital heart disease.
Looking for future studies?
Notify Me24 year–33 year
All sexes
Observational
Boston, Massachusetts, 02115, United States
Previously lethal, critical congenital heart disease (CHD) can now be treated effectively with surgical, catheter, and medical interventions. The resulting dramatic improvement in life expectancy has brought a major demographic shift, so that adult patients with CHD now outnumber children with CHD, even for complex conditions. Adult survivors are at increased risk of anxiety, depression, social difficulties, lower educational attainment, and underemployment. These psychosocial morbidities may be associated with deficits in executive functions (EFs) and other neurocognitive abilities that are prevalent in children and adolescents with CHD. Deficits in EFs, represented by measures of inhibitory control, working memory, cognitive flexibility, and decision-making, are highly dependent on the integrity of cortical and subcortical neural networks that continue to develop into early adulthood and can have a major adverse impact on self-regulation and management. The goal of this proposal is to bridge the gap in knowledge between known executive function deficits in childhood CHD and adult well-being. The investigators propose to accomplish our goal by studying subjects, now age 24-29 years, who were enrolled as infants in the Boston Circulatory Arrest Study and then studied with respect to neuropsychological and developmental function at ages 1, 2.5, 4, 8, and 16 years, as well as with brain MRI at 16 years. In Aim 1, the relationship of EFs to major dimensions of adult well-being will be explored. It is hypothesized that lower performance on EFs will be related to poorer overall well-being. The outcomes measured to determine well-being will be quality of life, neuropsychological function (e.g. social cognition, memory skills), mental health diagnosis and function (e.g. anxiety, depression), social relatedness, academic achievement, and adult independence (e.g. employment status, medical follow up). In Aim 2, the relationship of EFs to MRI-derived measures of brain structure, function, and connectivity will be determined. It is hypothesized that lower performance on EFs will be associated with lower global efficiency (integration) and higher modularity (segregation). The brain MRI outcomes will be measured using global white matter connectivity, regional cortical gray matter thickness, gray matter connectivity measured from interregional correlation in cortical thickness, and functional connectivity as defined by resting state functional magnetic resonance imaging. In Aim 3, longitudinal models will be used to analyze the association of adult well-being with earlier measures of EFs and other neurocognitive and mental health variables, as well as with earlier clinical variables and adolescent neuroimaging. The associations of adult well-being dimensions with childhood and adolescent EFs, other measures of mental health and cognitive function, adolescent brain MRI findings, and clinical variables will be explored. The ultimate goal is to identify early, modifiable risk factors for adult performance to guide the design of targeted treatment strategies that optimize educational achievement, employability, and quality of life in the burgeoning population of adults with CHD.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Study Group:
Inclusion criteria
Exclusion criteria
Control Group:
Control Inclusion Criteria
Control Exclusion Criteria
MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
Time frame: baseline
Linear analog scale, Quality of Life Survey
Time frame: baseline
Hospital Anxiety and Depression scale and the structured clinical interview for DSM-V
Time frame: baseline
Hospital Anxiety and Depression scale and the structured clinical interview for DSM-V
Time frame: baseline
structured clinical interview for DSM-V and Connors' Adult ADHD Rating Scales - Screening Version
Time frame: baseline
structured clinical interview for DSM-V
Time frame: baseline
Time frame: baseline
Time frame: baseline
Iowa Gambling Task (IGT)
Time frame: baseline
Time frame: baseline
Time frame: baseline
The NIH Toolbox Emotion Domain - The Social Relationships subdomain measures will be administered.
Time frame: baseline
Categories from the National health interview survey and Hollingshead four factor index
Boston Children's Hospital
Other
Acronym: BCAS-Adult
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04111549
Brain Diseases, Brain Injuries
San Francisco, California, United States
View Trial DetailsNCT05524324
Cardiovascular Abnormalities, Cardiovascular Diseases
Caen, France
View Trial DetailsNCT06843733
Cognition Disorders, Cognitive Dysfunction
Salaya, Changwat Nakhon Pathom, Thailand
View Trial DetailsNCT04121650
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Boston, Massachusetts, United States
View Trial Details